Md Nazir Hossen
Overview
Explore the profile of Md Nazir Hossen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dey A, Dwivedi S, Wang L, Hossen M, Neizer-Ashun F, Bieniasz M, et al.
Genes Dis
. 2022 Sep;
9(6):1415-1418.
PMID: 36157476
No abstract available.
2.
Hossen M, Wang L, Dwivedi S, Zhang Y, Rao G, Elechalwar C, et al.
Adv Sci (Weinh)
. 2022 Sep;
9(31):e2200491.
PMID: 36104215
By exploiting the self-therapeutic properties of gold nanoparticles (GNPs) a molecular axis that promotes the growth of high-grade serous ovarian cancer (HGSOC), one of the deadliest gynecologic malignancies with poorly...
3.
Yang W, Wang L, Fang M, Sheth V, Zhang Y, Holden A, et al.
Nano Lett
. 2022 Feb;
22(5):2103-2111.
PMID: 35166110
Nanoparticle modification with poly(ethylene glycol) (PEG) is a widely used surface engineering strategy in nanomedicine. However, since the artificial PEG polymer may adversely impact nanomedicine safety and efficacy, alternative surface...
4.
Seaberg J, Montazerian H, Hossen M, Bhattacharya R, Khademhosseini A, Mukherjee P
ACS Nano
. 2021 Jan;
15(2):2099-2142.
PMID: 33497197
Inorganic/organic hybrid nanosystems have been increasingly developed for their versatility and efficacy at overcoming obstacles not readily surmounted by nonhybridized counterparts. Currently, hybrid nanosystems are implemented for gene therapy, drug...
5.
Hossen M, Elechalawar C, Sjoelund V, Moore K, Mannel R, Bhattacharya R, et al.
Cancer Nanotechnol
. 2021 Jan;
12(1):1.
PMID: 33456622
Background: Ovarian cancer is one of the deadliest gynecological malignancies. While the overall survival of ovarian cancer patients has slightly improved in recent years in the developed world, it remains...
6.
Zhang Y, Elechalawar C, Hossen M, Francek E, Dey A, Wilhelm S, et al.
Bioact Mater
. 2020 Sep;
6(2):326-332.
PMID: 32954051
Cancer-associated fibroblasts (CAFs) are a major constituent of the tumor microenvironment (TME) and an important contributor to cancer progression and therapeutic resistance. Regulation of CAF activation is a promising strategy...
7.
Dey A, Prabhudesai S, Zhang Y, Rao G, Thirugnanam K, Hossen M, et al.
Sci Adv
. 2020 Sep;
6(27).
PMID: 32937467
The stringent expression of the hypoxia inducible factor-1α (HIF-1α) is critical to a variety of pathophysiological conditions. We reveal that, in normoxia, enzymatic action of cystathionine β-synthase (CBS) produces HS,...
8.
Rao G, Dwivedi S, Zhang Y, Dey A, Shameer K, Karthik R, et al.
EMBO Rep
. 2020 Aug;
21(10):e48483.
PMID: 32851774
MICU1 is a mitochondrial inner membrane protein that inhibits mitochondrial calcium entry; elevated MICU1 expression is characteristic of many cancers, including ovarian cancer. MICU1 induces both glycolysis and chemoresistance and...
9.
Hossen M, Wang L, Chinthalapally H, Robertson J, Fung K, Wilhelm S, et al.
Sci Adv
. 2020 Aug;
6(30):eaba5379.
PMID: 32743073
Gene silencing using small-interfering RNA (siRNA) is a viable therapeutic approach; however, the lack of effective delivery systems limits its clinical translation. Herein, we doped conventional siRNA-liposomal formulations with gold...
10.
Elechalawar C, Hossen M, McNally L, Bhattacharya R, Mukherjee P
J Control Release
. 2020 Mar;
322:122-136.
PMID: 32165239
When nanoparticles are introduced into biological systems, host proteins tend to associate on the particle surface to form a protein layer termed the "protein corona" (PC). Identifying the proteins that...